Biocon’s arm to purchase 7.69% stake in Syngene International for Rs 215.38 crore

10 Sep 2014 Evaluate

Biocon’s wholly owned subsidiary - Biocon Research (BRL), has entered into an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), to purchase the latter’s investment in Biocon’s research services subsidiary, Syngene International for an agreed consideration of Rs 215.38 crore. GE Capital had a 7.69% stake in Syngene.

Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology and toxicology.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

390.25 -5.00 (-1.27%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×